权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Basic and clinical studies for the targeting therapy by using the morphometrical analysis in malignant brain tumors.

利用形态测量分析对恶性脑肿瘤进行靶向治疗的基础和临床研究。

基本信息

批准号：
03454342
负责人：
YOSHII Yoshihiko
金额：
$ 0.64万
依托单位：
University of Tsukuba, Institution of Clinical Medicine
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1991
资助国家：
日本
起止时间：
1991 至 1992
项目状态：
已结题

项目摘要

Improved modern neuroimaging techniques and rigid immobilization systems alow confirmation of the target position relative to the proton beam at each treatment, treatment planning based on beam trajectory, dose at each anatomical point, bolus based on accurate assessment of density along each pixel, etc. Proton therapy in our institute showed that the patient could tolerate radiation doses 15-20% higher than those of conventional radiation therapy used. However, it was suggested that the doses needed 140-160 TDF and the tumor volume was less than 10 ml to cure the patients with malignant brain tumor. Therefore, proton beam will be a main instrument of the morphometric targeting therapy for the brain tumors. Neuroimaging is very helpful in estimating clinically the overall extent of the tumor and the peripheral margin. Gd-DTPA MRI can be used effectively in the diagnosis of tumor viability and malignancy after treatment. Furthermore, ^<201>Tl-SPECT appears to be effective for determination of the malignant viability of tumors. In the effectiveness of superselective 1 A chemotherapy of malignant tumors, the antitumor drug was transported into the tumor at an average rate of 6.3% of the total dose injected intra arterially. In calculating the ratio of the delivered ACNU dose to the tumor volume, ACNU of the average 320 mug/ml might be needed as the effective treatment. From DNA content analysis, it is suggested that the malignant brain tumors have different bilogical heterogeneity and its analysis requires further study for the morphometric targeting therapy.

改进的现代神经影像技术和刚性固定系统可以确认每次治疗时相对于质子束的目标位置、基于束轨迹的治疗计划、每个解剖点的剂量、基于沿每个像素的密度的准确评估的推注等。我们研究所的质子治疗表明，患者可以耐受比传统放射治疗高15-20%的辐射剂量。但有人建议，恶性脑肿瘤患者的治疗剂量需要140-160TDF且肿瘤体积小于10ml。因此，质子束将成为脑肿瘤形态计量靶向治疗的主要手段。神经影像学对于临床估计肿瘤的整体范围和外周边缘非常有帮助。 Gd-DTPA MRI 可有效用于诊断治疗后的肿瘤活力和恶性程度。此外， 201 T1-SPECT似乎对于确定肿瘤的恶性活力是有效的。在恶性肿瘤超选择性1A化疗的有效性中，抗肿瘤药物以平均动脉注射总剂量的6.3%的速度转运到肿瘤中。在计算所递送的ACNU剂量与肿瘤体积的比率时，可能需要平均320μg/ml的ACNU作为有效治疗。从DNA含量分析来看，恶性脑肿瘤具有不同的生物学异质性，其分析需要进一步研究形态计量学靶向治疗。